Get the Stockscreener App
2.47
4.26%
-0.11
After Hours:
2.47
Aileron Therapeutics Inc stock is traded at $2.47, with a volume of 93,775.
It is down -4.26% in the last 24 hours and down -32.70% over the past month.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
See More
Previous Close:
$2.58
Open:
$2.61
24h Volume:
93,775
Relative Volume:
1.21
Market Cap:
$53.51M
Revenue:
-
Net Income/Loss:
$-12.94M
P/E Ratio:
-0.8697
EPS:
-2.84
Net Cash Flow:
$-13.83M
1W Performance:
-13.94%
1M Performance:
-32.70%
6M Performance:
-33.24%
1Y Performance:
+32.80%
1-Day Range:
$2.33
$2.69
1-Week Range:
$2.33
$3.38
52-Week Range:
$1.61
$7.42
Aileron Therapeutics Inc Stock (ALRN) Company Profile
Name
Aileron Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN, MA
Compare ALRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ALRN | 2.47 | 53.51M | 0 | -12.94M | -13.83M | -2.84 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Aileron Therapeutics Inc Stock (ALRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Aileron Therapeutics Inc Stock (ALRN) Latest News
Aileron Therapeutics Reports Q3 2024 Financial Results - MSN
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Citizentribune
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 8.7% in October - MarketBeat
Aileron Therapeutics Inc (ALRN) Quarterly 10-Q Report - Quartzy
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis - AOL
Aileron reports promising phase 1b trial results for IPF treatment - Investing.com
Aileron reports promising phase 1b trial results for IPF treatment By Investing.com - Investing.com UK
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - Yahoo Finance
Advancium explores ALRN-6924 for pediatric eye cancer treatment - Investing.com India
Advancium explores ALRN-6924 for pediatric eye cancer treatment By Investing.com - Investing.com Canada
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma - PR Newswire
Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Drops By 14.2% - MarketBeat
Constrained Peptide Drugs Market Size, Scope and Share Analysis - InsightAce Analytic
Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Increases By 15.8% - MarketBeat
ALRNAileron Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis - Lelezard
University of Texas Texas AM Investment Management Co. Invests $4.93 Million in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat
Nantahala Capital Management LLC Raises Holdings in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 13.4% in September - MarketBeat
Alumis (NASDAQ:ALMS) Trading 4.8% Higher - MarketBeat
Keeping an Eye on Alx Oncology Holdings Inc (ALXO) After Insider Trading Activity - Knox Daily
Ready to Jump After Recent Trade: Alx Oncology Holdings Inc (ALXO) - SETE News
ALXO stock touches 52-week low at $1.87 amid market challenges - Investing.com
Alumis (NASDAQ:ALMS) Shares Gap Down to $11.86 - MarketBeat
Market Highlights: Alector Inc (ALEC) Ends on a Low Note at 5.45 - The Dwinnex
What is the investor’s view on Alx Oncology Holdings Inc (ALXO)? - US Post News
Insider Sale Alert: Aldeyra Therapeutics Inc [ALDX] – Is it Time to sell? - Knox Daily
Alector (NASDAQ:ALEC) Shares Down 5.6% - MarketBeat
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - Nasdaq
Market Update: Alx Oncology Holdings Inc (ALXO) Sees Negative Movement, Closing at 2.07 - The Dwinnex
Keith Johns Joins Allurion's Board Of Directors - MPO-mag
HighVista Strategies LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Taking on analysts’ expectations and winning: Alumis Inc. (ALMS) - SETE News
Healius sells Lumus imaging unit to Affinity for USD 657M - Medical Buyer
Australia Medical Diagnostics Firm Healius Sells Lumus to Affinity for $657 Million - BNN Bloomberg
Renaissance Technologies LLC Sells 800 Shares of Alexander’s, Inc. (NYSE:ALX) - Defense World
Alector (NASDAQ:ALEC) Stock Price Up 9% - Defense World
1,959,896 Shares in Alumis Inc. (NASDAQ:ALMS) Bought by SR One Capital Management LP - MarketBeat
Aileron Therapeutics Inc Inc. (ALRN) Price Performance: The Role of Supply and Demand - The InvestChronicle
Closing Bell Recap: Aileron Therapeutics Inc (ALRN) Ends at 2.91, Reflecting a 9.81 Upturn - The Dwinnex
Altair Engineering: Rating Downgrade As Near-Term Upside Is Limited (NASDAQ:ALTR) - Seeking Alpha
Alumis (NASDAQ:ALMS) Shares Down 2.6% - MarketBeat
Alesi Surgical wins FDA clearance for smoke management device and lands new funding - Mass Device
Alector, Inc. (NASDAQ:ALEC) Short Interest Down 5.7% in August - Defense World
Allurion Technologies Inc. (NYSE:ALUR) Short Interest Up 8.6% in August - Defense World
Australia's ALS tumbles on subdued half-year forecast - XM
Market cap of Allarity Therapeutics Inc [ALLR] reaches 4.22M – now what? - The DBT News
Alumis (NASDAQ:ALMS) Stock Price Up 5.3% - Defense World
Alexander's (NYSE:ALX) Hits New 52-Week High at $248.10 - MarketBeat
In the Green: Alector Inc (ALEC) Closes at 5.64, Up/Down -0.70 from Previous Day - The Dwinnex
Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter
Aileron Therapeutics Inc Stock (ALRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aileron Therapeutics Inc Stock (ALRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 14 '24 |
Sale |
3.30 |
1,900 |
6,270 |
1,751,256 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 10 '24 |
Sale |
3.30 |
9,577 |
31,604 |
1,768,250 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 12 '24 |
Sale |
3.25 |
9,342 |
30,362 |
1,753,156 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 11 '24 |
Sale |
3.26 |
5,752 |
18,744 |
1,762,498 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 05 '24 |
Sale |
3.30 |
6,291 |
20,760 |
1,783,851 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 06 '24 |
Sale |
3.29 |
4,284 |
14,104 |
1,779,567 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 07 '24 |
Sale |
3.26 |
1,740 |
5,664 |
1,777,827 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
May 01 '24 |
Sale |
4.21 |
20,315 |
85,473 |
1,779,306 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Apr 29 '24 |
Sale |
4.95 |
10,746 |
53,182 |
1,799,711 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Apr 30 '24 |
Sale |
4.97 |
90 |
448 |
1,799,621 |
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):